Skip to main content
. 2023 Sep 26;9(10):e20428. doi: 10.1016/j.heliyon.2023.e20428

Table 5.

Chalcone derivatives investigated against HSV.

Compound(s) “Chemical name(s)” Virus subtype Study model(s) Results Inhibition mechanism Refs.
“5-(4-chlorophenyl)-3-(4-hydroxy-3-methylphenyl)-4,5-dihydro-1H-1-pyrazolyl-4-pyridyl methanone” HSV-1 In vitro Minimum inhibitory concentration (MIC): >8 μg/mL
(against HSV-1)		 Replication inhibitory activity [98]
Chalcone derivatives isolated from Millettia leucantha KURZ “2′,4′,6′-Trimethoxy-3,4-methylenedioxydihydrochalcone, 3-(1,3-benzodioxol-5-yl)-1-(2,4-dimethoxyphenyl)-3-methoxypropan-1-one” HSV-1 and HSV-2 In vitro IC50: 15.5 μg/mL (against HSV-1) and 17.0 μg/mL (against HSV-2) N/A [99]
3,5-Bis(arylidene)-4-piperidones “(E)-1-Methyl-3,5-bis(2-thienylidene)-4-piperidone” HSV-1 In vitro IC50: 0.66 μM N/A [100]

HSV-1: herpes simplex virus type 1, HSV-2: herpes simplex virus type 2, IC50: Half maximal inhibitory concentration, MIC: Minimal inhibitory concentration.